Pain typically accompanies acute herpes zoster. In a proportion of patients, herpes zoster pain persists well beyond rash healing. This persisting pain is termed post-herpetic neuralgia (PHN). Because of the substantial personal and economic burdens caused by PHN, studies of the pathophysiology of herpes zoster pain and of the efficacy of antiviral treatment in reducing prolonged pain are of great importance. Different methods have been used to examine pain in research on herpes zoster and in clinical trials, making it difficult to compare across studies. There is substantial evidence, however, that demonstrates the importance of distinguishing acute pain from PHN. Several differences have been found between acute herpes zoster pain and PHN, including pathophysiological findings, risk factors and pain quality. Recommendations for the design and analysis of future trials of antiviral agents in herpes zoster have been recently proposed. These include a definition of PHN and recommended secondary end points for future trials. Adopting these recommendations in future research on herpes zoster pain, and in the design and analysis of future trials, will facilitate comparisons across studies of the pathophysiology and prevention of PHN.
Introduction
Most patients with herpes zoster suffer from pain. The nature and duration of this pain is variable. Pain that persists beyond a defined period following healing of the herpes zoster rash is termed post-herpetic neuralgia (PHN). PHN is a common complication of herpes zoster, and like the pain associated with acute herpes zoster its characteristics and duration are highly variable (Dworkin &Portenoy, 1996) . Well-established PHN is often accompanied by physical and occupational disability, increased healthcare utilization and psychological distress. In some cases, the pain is severe, refractory to treatment and persistent for years.
Some authors have defined PHN as pain persisting after the herpes zoster rash has healed (Burgoon et al., 1957; Bamford & Boundy, 1968) . Others have defined it as pain persisting beyond a specified interval after rash onset -for example, 4 weeks (Rogers & Tindall, 1971 ), 6 weeks (Brown, 1976) , 3 months (Max et al., 1988) or 6 months (Harding et al., 1987) . Yet another approach is to consider PHN as pain persisting beyond a specified interval after rash healing -for example, 1 month (Rowbotham et al., 1995) or 3 months (Rowbotham & Fields, 1989) .
Because of the existence of these different definitions, the use of PHN as a clinical end point in research on herpes zoster pain has recently become controversial. It has been suggested that pain in herpes zoster should be considered ' ... as a continuum, rather than distinguishing acute pain from an arbitrary definition of postherpetic neuralgia. ' (Huff et al., 1993) . Several recent studies have used this approach to examine the efficacy of antiviral medications and other treatments in reducing the duration of herpes zoster pain (Crooks et al., 1991; Huff et al., 1993; Degreef et al., 1994; Wood et al, 1994 Wood et al, , 1996 Beutner et al., 1995; Whitley et al., 1996) . In these trials, the end point used in evaluating treatment efficacy is the time from enrolment to complete cessation of all zoster-associated pain (ZAP); no distinction is made between acute pain and PHN when herpes zoster pain is examined in this manner (Wood et al, 1995) .
Such analyses of herpes zoster pain considered as a continuum can provide a worthwhile overview of factors ssociated with pain duration, not only in studies of the efficacy of treatments for reducing pain duration, but also in research on risk factors for persistent herpes zoster pain. One important advantage of this approach is that no assumption is required regarding the point at which PHN begins. On the other hand, to the extent that acute herpes zoster pain and PHN differ clinically and have different pathophysiologies, examining pain only as a continuum would be misleading and could impede progress in understanding herpes zoster. The purpose of defining PHN in clinical trials is not to define when PHN begins, but rather to identify those patients who have persisting pain. This makes it possible to evaluate the beneficial effects of antiviral therapy on this important clinical outcome. Examining a continuum of pain duration does not do this.
In this article, the results of research examining the differences between acute herpes zoster pain and PHN will be reviewed. Each of the studies discussed can be criticized and none provide unequivocal evidence that acute pain and PHN are completely different conditions. Nevertheless, in addressing the distinction between acute herpes zoster pain and PHN from very different perspectives, the data provide considerable support for the validity and importance of examining acute herpes zoster pain and PHN separately.
Acute pain versus chronic pain in herpes zoster
Perhaps the most obvious question to ask regarding the difference between acute herpes zoster pain and PHN is whether the quality of the pain differs. To address this question, responses to the McGill Pain Qpestionnaire, a widely used measure consisting of various adjectives that describe pain (Melzack, 1975) , have been compared in samples of patients with acute herpes zoster and PHN (Bhala et al., 1988; Bowsher, 1993) . The results of this research indicate that sharp, stabbing pain is more common in patients with acute herpes zoster than in patients with PHN, whereas burning pain is more common in PHN and is much less likely to be reported by patients with acute zoster.
With respect to the natural history of pain in herpes zoster, several groups of investigators have recently reported that herpes zoster pain can be discontinuous, with pain-free intervals occurring (Watson et al., 1991b; Huff et al., 1993) . The existence of such pain-free intervals is not consistent with considering herpes zoster pain as a continuum extending from the acute infection through to the development of chronic pain. Indeed, in the aciclovir trial conducted in the USA, ' ...four patients (2 aciclovir and 2 placebo subjects) who first reported pain at 1 month after enrolment continued to report pain until the seventh month. ' (Huff et al., 1993) . These data suggest that herpes zoster patients can develop PHN without having had Time to loss of pain from enrolment in patients whose pain persisted <30 days from enrolment and in patients who had pain~30 days fallowing enrolment. Adapted from Boon & Griffin (1996) .
acute pain. Moreover, the existence of pain-free intervals means that complete cessation ofpain considered as a continuum can never be determined with certainty; individuals free of pain at the end of a study may have a recurrence of pain at a later date. However, because PHN is defined as the persistence of pain at a given point in time, typically following the acute phase or several months later, the existence of pain-free intervals is not problematic in conducting analyses of the proportion of patients who have developed PHN.
The results of several studies have suggested that risk factors for acute pain in herpes zoster and PHN differ. In two studies that examined patients whose pain resolved within 30 days of rash onset, cessation of this acute pain was found to occur at the same times in young and old patients (Bean et al., 1993; Boon & Griffin, 1996) . However, when the duration of pain persisting beyond 30 days (i.e. PHN) was examined in one of these studies, pain duration was greater in older patients than in younger patients (Boon & Griffin, 1996) (Fig. 1) . These data suggest that there is no relationship between age and the duration of acute herpes zoster pain, but that older age is associated with a greater duration of PHN. Psychosocial distress may be an additional risk factor that discriminates acute herpes zoster pain from PHN. In a preliminary study with a small sample of patients, greater acute pain severity was the only factor that predicted the presence ofwhat was considered short-term herpes zoster pain (pain at 2 months after rash onset). However, both greater acute pain severity and psychosocial distress predicted the development of PHN, defined as pain at 4 months after rash onset (Dworkin et al., 1992) .
Differences in the pathophysiologies of acute herpes zoster pain and PHN would provide compelling evidence Table 1 . The impact of post-herpetic neuralgia in the UKa for distinguishing between the two conditions. In postmortem studies conducted by Watson et al. (1988 Watson et al. ( , 1991a , dorsal horn atrophy and pathological changes in the sensory ganglion were found on the affected side (and not on the unaffected side) in patients with PHN, but not in patients with a history of herpes zoster whose pain did not persist. These pathological features were therefore only characteristic of those patients with PHN. Other findings, such as marked loss of myelin in the peripheral nerve and sensory root, were found in all herpes zoster patients studied, i.e. both those who developed PHN as well as those who did not. Although the results of this programme of research are based on a small series of patients, they provide important evidence consistent with the suggestion that different pathophysiological mechanisms account for acute herpes zoster pain and PHN (Bennett, 1994) .
Additional evidence that acute herpes zoster pain and PHN may have distinct pathophysiologies is provided by their different responses to oral steroid treatment. The results of several studies suggest that such treatment has a beneficial effect on acute herpes zoster pain but does not reduce the incidence ofPHN (Esmann et al., 1987; Wood et al., 1994; Whitley et al., 1996) and is not effective once PHN has developed (Portenoy et al., 1986) .
The results of these studies of clinical features, natural history, risk factors and pathophysiology provide support for the importance of distinguishing acute herpes zoster pain from PHN. Another reason to distinguish between acute and chronic pain in herpes zoster is the very great difference in the burdens imposed by the two conditions. These burdens are of diverse types: healthcare utilization costs, occupational disability and forced unemployment, psychological distress and impairments in social functioning, including relationships with family and friends. In a recent study by Davies et al. (1994) , it was reported that 59% of a sample of PHN patients attending a pain clinic in Liverpool, UK, had taken time off from their usual activities and that these patients had been prevented from pursuing these activities for up to 16 years (the average was 1.4 years). The results of this study also demonstrated the impact of PHN on healthcare utilization. As shown in Table 1 , patients in this study had visited their general physicians an average of 19 times (range: 0-69 visits) and "Data drawn from Davies ef ol. (1994) . Indeed, it is generally recognized that the only reason why herpes zoster is a significant clinical concern in immunocompetent patients is that pain persists well beyond rash healing in some patients. There is another important reason to distinguish acute pain from PHN in examining herpes zoster pain. The majority of herpes zoster patients only suffer from acute pain and do not develop PHN. Thus, results for acute pain patients may mask results for patients with PHN if the two are not analysed separately. The statistical significance of analyses of herpes zoster pain as a continuum may not reflect what would be found in analyses of only those patients with PHN. As shown in Fig. 2 , in an examination of 146 placebo-treated herpes zoster patients participating in a double-blind trial of famciclovir, the median duration of herpes zoster pain examined as a continuum (ZAP) was 26 days. This exceeded the median duration of acute pain in patients whose pain did not persist beyond rash healing by only 4 days . The median duration of PHN, however, was over 6 months (189 days), reflecting the fact that PHN is a chronic pain syndrome. These data indicate that analyses of zoster pain treated as a continuum may be influenced excessively by patients who only have acute pain.
None of the studies discussed in this section provide unequivocal evidence that acute herpes zoster pain and PHN are completely separate conditions. However, the results of these studies do provide considerable support for the validity and importance of examining acute herpes zoster pain and PHN separately. Furthermore, the results suggest that analyses of herpes zoster pain as a simple continuum of pain duration may fail to reveal important aspects of PHN that are not shared with acute herpes (1997) .
nificant pain should be considered as pain of at least moderate severity. One approach to defining such pain is pain reported by the patient to be~3 on a 0-10 numerical rating scale. This criterion is based on the results of Lydick et al. (1995) , in which ratings of acute pain in herpes zoster patients of 1 or 2 on a 0-10 scale were rarely accompanied by adverse impacts on quality of life. It was further recommended that two analyses should be conducted: PHN prevalence, assessed as point prevalence of clinically significant pain at 3 months; and PHN duration, assessed as duration of clinically significant pain in those patients with PHN. Patients should be assessed for 6 months following enrolment, regardless of any pain-free interval.
With respect to the assessment of PHN duration, the recommendations emphasized that only patients with PHN should be included in the data analysis. An alternative method has been employed to analyse PHN duration in which all patients enrolled are examined. Using this method, patients who do not have PHN are assigned a duration ofPHN of 0 days (Beutner et al., 1995; Wood et al., 1996) . The number of such patients included in different treatment groups, however, may not be balanced. The effect of including patients who do not develop PHN and designating them as having a time to event of 0 days is illustrated in Fig. 3 , which is based on placebo-treated patients from a large herpes zoster trial. As the percentage of patients who do not have PHN (those assigned a value of 0 days) increases, the difference between the groups also increases. This results in an increase in the hazard ratio and a decrease in the P value when the Cox Proportional Hazards model is used to analyse the data. It is also clear that the inclusion of patients who do not develop PHN results in an 'artificially' lowered median duration ofPHN.
The secondary endpoints recommended for future herpes zoster trials were: duration of clinically significant ZAP, with clinically significant defined as above; duration of ZAP of any severity; duration and prevalence ofPHN, defined as pain of any severity of~3 months duration from enrolment; duration and severity of acute pain (in patients who only have acute pain); pain interference with activities of daily living; health-related quality of life; and analgesic use.
Recommendations: pain measurement
There are at least four different approaches that can be used to measure pain intensity in studies of herpes zoster: visual analogue scales, numerical rating scales, verbal rating scales and the McGill Pain Questionnaire (Melzack, 1975 Time from enrolment(days) Beutner et al., 1995; Tyring et al., 1995; Wood et al., 1996) .
In March 1996 in Miami, Florida, USA, a group of 12 specialists in infectious diseases, dermatology, virology, geriatrics and pain met to review the published data and assess the strengths and weaknesses of the various research designs and methods of analysis that have been used in herpes zoster trials. Based on this review, recommendations were proposed for the design and analysis of future trials of antiviral agents in herpes zoster . The major recommendations concerned the assessment of pain in future trials; these will be summarized briefly in the remainder of this article. Consistent with the literature reviewed above, it was recommended that the primary endpoint focus on PHN, defined as clinically significant pain of a duration equal to or greater than 3 months from enrolment. Clinically sig-zoster pain. Nevertheless, these two different approaches to the persistence ofpain in herpes zoster are not mutually exclusive; data on herpes zoster pain collected on multiple occasions beginning during the acute infection and continuing for several months thereafter can be analysed by calculating the prevalence and duration ofPHN, as well as by examining a continuum of pain duration. recommended for use in many situations. Verbal rating scales and the McGill Pain Questionnaire (Melzack, 1975) can be problematic in that they may need to be translated for use in some countries; in addition, the latter, which was designed as an interview, can be time consuming. However, many different language versions of the McGill Pain Qpestionnaire exist, and a shorter version is available (Melzack, 1987) . Assessment of pain severity should include pain experienced over the last 24 h, plus the worst pain since the last assessment.
Five distinct types of pain are associated with acute herpes zoster and PHN (Dworkin & Portenoy, 1996; Dworkin, 1997; Dworkin et al., 1997) . These are steady throbbing pain, steady burning pain, intermittent sharp or shooting pain, allodynia (either burning or sharp/shooting pain in response to a stimulus that does not normally provoke pain) and hyperpathia. Bowsher (1993) has reported that burning pain appears to be less common in PHN patients treated with an antiviral during their acute infection; these data suggest that it would be worthwhile to investigate the impact of antiviral therapy on the different qualities of herpes zoster pain in future trials. These data could be collected with either specific questions designed to capture this information or by using the McGill Pain Qpestionnaire.
Conclusions
To date, the above recommendations have not been applied simultaneously in any single herpes zoster trial. Hopefully, future trials by academia, government and industry will do so. This will increase the comparability of data collected in antiviral trials, and thereby facilitate evaluations of the relative efficacy of different antiviral agents.
Herpes zoster is expected to increase as the mean age of the population increases, and because PHN is more common in older individuals its prevalence is also likely to increase substantially in the next few decades. Because well-established PHN can be very difficult to treat, a greater understanding of its pathogenesis and effective methods of prevention are needed. These goals will only be achieved by thoughtful attention to the assessment of pain in herpes zoster.
